FDA
FDA biologics chief Vinay Prasad to leave agency at end of April
AI에 의해 보고됨 AI에 의해 생성된 이미지 사실 확인됨
Dr. Vinay Prasad, who leads the FDA division that oversees vaccines and other biological products, will leave the agency at the end of April, FDA Commissioner Marty Makary told staff in an email. It will be Prasad’s second departure in less than a year after a brief exit last summer amid clashes over high-profile drug and vaccine reviews.
The FDA has cleared Dexcom’s Stelo Glucose Biosensor System for use by people ages 2 and older who do not use insulin. The decision, announced June 12, makes Stelo the first over-the-counter continuous glucose monitor approved for children.
AI에 의해 보고됨
The U.S. FDA has approved Afrezza for children and adolescents with diabetes ages 6 and older. MannKind Corporation held a conference call on May 29, 2026, to discuss the decision.
A federal judge in Texas has issued a ruling limiting the FDA's approval of mifepristone, the primary drug used in medication abortions. The decision revives a long-standing lawsuit challenging the drug's safety and regulatory process. This comes amid ongoing legal battles over abortion access following the Supreme Court's overturning of Roe v. Wade.
AI에 의해 보고됨
Republican Senator Josh Hawley from Missouri has sharply criticized the Food and Drug Administration for approving a new abortion drug, raising concerns about women's safety and the agency's trustworthiness. In a letter to FDA Commissioner Robert Califf, Hawley accused the agency of prioritizing politics over science. The move highlights ongoing debates over abortion access and regulatory oversight.
The U.S. Food and Drug Administration has granted accelerated approval to Forzinity, the first treatment for Barth syndrome, a rare X-linked genetic disorder primarily affecting males. Developed by Stealth Biotherapeutics, the therapy targets mitochondrial dysfunction underlying the condition, offering new hope for patients with this life-threatening disease. This milestone follows years of advocacy and highlights progress in addressing ultra-rare disorders.
AI에 의해 보고됨
The U.S. Food and Drug Administration has approved a new device for detecting hypertension, integrating advanced sensor technology. This innovation aims to improve early diagnosis and management of the condition.
Inovio Pharmaceuticals reviews Q1 results and INO-3107 FDA status
2026년 04월 30일 05시 54분Syntara reports positive FDA feedback on amsulostat trial
2026년 04월 13일 22시 13분FDA approves Travere Therapeutics' FILSPARI for FSGS
2026년 01월 01일 08시 26분US FDA approves first oral pill for thalassaemia anaemia
2025년 11월 20일 04시 09분Paradromics receives FDA approval for brain implant trial
2025년 10월 02일 00시 19분Senate confirms Robert Califf as FDA commissioner
2025년 09월 30일 00시 32분Supreme Court upholds FDA approval of mifepristone
2025년 09월 30일 00시 32분FDA issues final rule on clinical trials diversity
2025년 09월 26일 00시 23분Coalition Opposes FDA's Proposed Ban on 7-OH Substance
2025년 09월 22일 00시 09분FDA Approves Injectable Form of Merck's Keytruda